Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2001 1
2002 9
2003 9
2004 10
2005 28
2006 18
2007 16
2008 15
2009 13
2010 21
2011 14
2012 21
2013 16
2014 28
2015 22
2016 31
2017 20
2018 14
2019 17
2020 10
2021 7
2022 13
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Results by year

Filters applied: . Clear all
Page 1
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Among authors: zielinski cc. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Subbiah V, et al. Among authors: zielinski c. J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26. J Clin Oncol. 2018. PMID: 29072975 Free PMC article. Clinical Trial.
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Guerrero-Zotano Á, et al. Among authors: zielinski c. Clin Cancer Res. 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. Clin Cancer Res. 2023. PMID: 36749874 Free PMC article. Clinical Trial.
Triple-negative breast cancer.
Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Bartsch R, et al. Among authors: zielinski cc. Wien Med Wochenschr. 2010 Apr;160(7-8):174-81. doi: 10.1007/s10354-010-0773-6. Wien Med Wochenschr. 2010. PMID: 20473728 Free article. Review.
How I treat cancer special issue.
Zielinski CC. Zielinski CC. ESMO Open. 2019 May 1;4(Suppl 2):e000514. doi: 10.1136/esmoopen-2019-000514. eCollection 2019. ESMO Open. 2019. PMID: 31231575 Free PMC article. No abstract available.
CSCO joins ESMO Open-Cancer Horizons.
Zielinski CC, Wu YL. Zielinski CC, et al. ESMO Open. 2016 Nov 18;1(5):e000120. doi: 10.1136/esmoopen-2016-000120. eCollection 2016. ESMO Open. 2016. PMID: 27933216 Free PMC article. No abstract available.
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual J, Gil-Gil M, Proszek P, Zielinski C, Reay A, Ruiz-Borrego M, Cutts R, Ciruelos Gil EM, Feber A, Muñoz-Mateu M, Swift C, Bermejo B, Herranz J, Margeli Vila M, Antón A, Kahan Z, Csöszi T, Liu Y, Fernandez-Garcia D, Garcia-Murillas I, Hubank M, Turner NC, Martín M. Pascual J, et al. Among authors: zielinski c. Clin Cancer Res. 2023 Oct 13;29(20):4166-4177. doi: 10.1158/1078-0432.CCR-23-0956. Clin Cancer Res. 2023. PMID: 37490393 Free PMC article.
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations.
Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski C. Caglevic C, et al. Among authors: zielinski c. JCO Glob Oncol. 2022 Aug;8:e2200123. doi: 10.1200/GO.22.00123. JCO Glob Oncol. 2022. PMID: 35994695 Free PMC article. Review.
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, Pinto C, Yamaguchi K, Yoshino T, Zielinski C, Esser R, Tabernero J. Bokemeyer C, et al. Among authors: zielinski c. Future Oncol. 2024 Mar;20(7):393-407. doi: 10.2217/fon-2023-0282. Epub 2023 Oct 18. Future Oncol. 2024. PMID: 37850363 Free article. Review.
Bevacizumab treatment for advanced breast cancer.
Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Alvarez RH, et al. Among authors: zielinski c. Oncologist. 2011;16(12):1684-97. doi: 10.1634/theoncologist.2011-0113. Epub 2011 Oct 5. Oncologist. 2011. PMID: 21976315 Free PMC article. Review.
318 results